Clinical trial data from large cardiovascular outcome studiesincluding LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide)have not demonstrated increased fracture risk among patients taking GLP-1 receptor agonists compared with placebo
Examples: Using Ozempic (semaglutide) for weight loss is off-label Zepbound is the FDA-approved version specifically labeled for obesity Why this matters: Off-label prescribing can be appropriate, but it may affect insurance coverage and requires careful follow-up and monitoring
Hazen, M.D., Ph.D., senior author of the study and section head of Preventive Cardiology & Rehabilitation at the Cleveland Clinic
Int Congress for Complementary Medicine Research, London, UK, 2013
Kondo H, Takahashi M, Niki E